StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval
September 19, 2016 9:59 AM
Sarepta Therapeutics (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Momentum Movers
Trader Talk
Trading Halts
Next Articles
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM
Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
September 19, 2016 1:37 PM
Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform
September 19, 2016 1:29 PM
Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval
September 19, 2016 1:08 PM
Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
September 19, 2016 11:21 AM
Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer
September 19, 2016 10:40 AM
FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen
September 19, 2016 9:52 AM
Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
September 19, 2016 9:51 AM
Sarepta Therapeutics (SRPT) Halted on LUDP
September 19, 2016 9:51 AM
